What is radioligand therapy and does it work for Pancreatic Cancer

Radioligand Therapy and Pancreatic Cancer

What is Radioligand Therapy?

Radioligand therapy is a precision treatment approach that combines imaging and targeted therapy into one powerful tool. Here's how it works:

The Basic Concept: Radioligands are molecules that are "tagged" with radioactive particles. These tagged molecules are designed to seek out and attach to specific proteins found on cancer cells. Once attached, the radioactive component delivers targeted radiation directly to the tumor cells while sparing healthy tissue.

Think of it like a guided missile—the ligand (molecule) is the guidance system that finds cancer cells, and the radioactive component is the payload that destroys them.

Two-in-One Approach:

• Imaging function: A diagnostic version helps doctors "see" where cancer cells are located, even finding very small metastases (spread) that other imaging methods might miss
• Treatment function: A therapeutic version delivers radiation therapy directly to those same cancer cells

Current Status in Pancreatic Cancer

The Promising News: According to recent research presented at the 2025 AACR Annual Meeting, radiotheranostics (the combined imaging and treatment approach) is now being investigated specifically for pancreatic adenocarcinoma. A first-in-human safety study conducted at UC Davis Health evaluated this approach in 36 patients with locally advanced or metastatic pancreatic cancer.

Key Findings from the Study:

• Safety: No severe adverse events were reported, and radiation exposure was safe
• Detection capability: The radioligand approach was able to identify metastases in the liver, lung, bone, and brain that were too small to be seen by standard imaging methods (CT, MRI, PET scans)
• Early treatment signal: Some patients showed potential loss of tumor uptake on repeat imaging, suggesting possible tumor response, though this was an early-stage safety study

Why Radioligands Haven't Been Developed Yet for Pancreatic Cancer

According to Dr. [removed] Strickler (Duke University), radioligands have had great success in other cancers, particularly prostate cancer. However, pancreatic cancer presents unique challenges:

Requirements for Radioligand Success: For a radioligand to work effectively, you need:

1. A protein target that is universally expressed on cancer cells
2. That protein should have low or no expression on normal healthy tissue
3. An effective radioactive component to attach to it

The Pancreatic Cancer Challenge: While targets like CA 19-9 (a protein associated with pancreatic cancer) exist, developing an effective radioligand for pancreatic cancer has proven technically difficult. Dr. [removed] notes: "There's no reason why you could not develop a radioligand for pancreas cancer... You just have to find the protein and the target and engineer that molecule. I'm not aware of anything being developed though, strangely enough, for pancreas cancer."

What's Next?

The research is in early stages, but researchers are optimistic. The UC Davis study plans to:

• Move into multi-dosing approaches (giving treatment multiple times)
• Test other radioactive isotopes
• Explore combination approaches with other therapies
• Extend research to other cancer types including non-small cell lung cancer and metastatic breast cancer

Questions to Ask Your Oncologist

If you're interested in radioligand therapy or emerging precision medicine approaches:

1. "Are there any clinical trials available for radioligand therapy or radiotheranostics in pancreatic cancer that I might be eligible for?"

2. "What other precision medicine or targeted therapy options exist for my specific tumor mutations?"

3. "Are there any early-phase studies (Phase 1 or Phase 1b) that might be appropriate for my stage of disease?"

4. "How can I stay informed about new developments in radioligand therapy as they emerge?"

5. "What resources are available to help me find clinical trials, such as ClinicalTrials.gov or advocacy organization trial databases?"

Bottom Line

Radioligand therapy shows genuine promise for pancreatic cancer based on early safety data and its proven success in other cancers. However, it's still in the research phase specifically for pancreatic cancer. The approach represents an exciting direction in precision medicine—using advanced imaging to find cancer and targeted therapy to treat it simultaneously. As Dr. [removed] notes, these types of innovations are essential because "pancreas cancer is extraordinarily difficult to cure" and we need new approaches beyond traditional chemotherapy.

---

Sources:

• Let's Win Pancreatic Cancer: "Highlights from the 2025 AACR Annual Meeting" - Radiotheranostics research
• CancerPatientLab Webinar: "Navigating Pancreatic Cancer" (John Strickler, MD) - Discussion of radioligand development challenges and opportunities

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.